No Data
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
CANBRIDGE-B (01228.HK) received Shareholding of 19.5167 million ordinary shares from JPMorgan, valued at approximately 2.2503 million Hong Kong dollars.
On December 24, it was reported that according to the documents disclosed by the Hong Kong Stock Exchange on December 24, JPMorgan (JPMORGANCHASECO) increased its shareholding in CANBRIDGE-B (01228.HK) by 19.5167 million shares of common stock on December 18 at an average price of HKD 0.1153 per share on the market and HKD 0.1151 per share off-market, with a total value of approximately HKD 2.2503 million. After the increase, JPMorgan's latest number of shares held is 23.764 million, and its good warehouse ratio rose from 0.99% to 5.59%. Image source: Stock exchange equity disclosure.
Beihai Kangcheng announced that Mai Ruibei for the treatment of PFIC cholestatic pruritus has been approved for sale in Taiwan.
Beihai Kangcheng announced that Mireb will be applicable to ALGS patient populations in Taiwan for more than 2 months.
Express News | The USA Biological Security Act was not included in the CR bill.
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
